Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries. Going forward, the Company is focused on becoming a leader in European specialty, off-patent medicines.
Company profile
Ticker
CXRXF
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Concordia Healthcare Corp., Concordia International Corp.
SEC CIK
Latest filings (excl ownership)
15F-12B
Securities registration termination (foreign)
26 Nov 19
15-12B
Securities registration termination
28 Jan 19
6-K
Current report (foreign)
6 Dec 18
6-K
Current report (foreign)
29 Nov 18
6-K
Special Meeting of Holders of Limited Voting Shares
29 Nov 18
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Nov 18
6-K
Concordia International Corp. Announces Third Quarter 2018 Results
14 Nov 18
6-K
Current report (foreign)
8 Nov 18
6-K
Concordia International Corp. Announces Release Date for Third Quarter 2018 Results
1 Nov 18
6-K
Concordia International Corp. Adds European Pharmaceutical Industry Expert to its Board of Directors
29 Oct 18
Latest ownership filings
SC 13D/A
Concordia International Corp.
2 Oct 18
SC 13D
Concordia International Corp.
17 Sep 18
SC 13D
Concordia International Corp.
17 Sep 18
SC 13G
Concordia International Corp.
17 Sep 18
SC 13G/A
Concordia International Corp.
14 Feb 17
SC 13G
Concordia International Corp.
15 Aug 16
SC 13D
Beneficial ownership report
2 Nov 15
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|